Margaret M Wagner Selected Research

N- ((5- bromo- 2- thienyl)sulfonyl)- 2,4- dichlorobenzamide

1/2013	A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound, administered as a 24-h continuous infusion in patients with advanced solid tumors.
11/2011	A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Margaret M Wagner Research Topics

Disease

4	Neoplasms (Cancer) 01/2013 - 03/2002
1	Neutropenia 01/2013
1	Thrombocytopenia (Thrombopenia) 01/2013

Drug/Important Bio-Agent (IBA)

2	N- ((5- bromo- 2- thienyl)sulfonyl)- 2,4- dichlorobenzamideIBA 01/2013 - 11/2011
2	SodiumIBA 01/2013 - 11/2011
2	Pharmaceutical PreparationsIBA 01/2013 - 09/2004
1	Paclitaxel (Taxol)FDA LinkGeneric 09/2004
1	cryptophycin 1IBA 09/2004
1	Biological ProductsIBA 09/2004
1	Doxorubicin (Adriamycin)FDA LinkGeneric 09/2004
1	cryptophycin 52 (cryptophycin-52)IBA 09/2004
1	multidrug resistance-associated protein 1IBA 03/2002
1	Vincristine (Oncovin)FDA LinkGeneric 03/2002
1	LY 402913IBA 03/2002

Therapy/Procedure

1	Intravenous Infusions 01/2013